TFRC and Alzheimer disease: To address this problem, a “brain shuttle” approach has been developed that fuses the C-terminus of a monoclonal antibody against Aβ, the peptide that accumulates in the brain of AD patients, to an anti-TfR Fab, which facilitates the BBB transcytosis of an attached immunoglobulin [57].